MedPath

The PLCRC substudy Ultra high field 7.0 Tesla MR Spectroscopy to monitor capecitabine metabolism in liver metastases - a proof of concept study

Withdrawn
Conditions
bowel cancer
Colorectal cancer
10017990
Registration Number
NL-OMON43450
Lead Sponsor
niversitair Medisch Centrum Utrecht
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Withdrawn
Sex
Not specified
Target Recruitment
26
Inclusion Criteria

-18 years or older.
-Patients with liver metastases measurable according to RECIST in metastatic colorectal cancer.
-Patients that are planned to start with capecitabine and bevacizumab treatment as determined according to Dutch guidelines.
-Informed consent for longitudinal data collection according to the PLCRC study protocol.

Exclusion Criteria

• Patients receiving triple chemotherapy for mCRC.
• Patients that received or currently receive any other kind of systemic therapy for cancer.
• Patients that received any prior radiotherapy or surgery in the liver.
• Patients with a dihydropyrimindine dehydrogenase (DPD) deficiency (heterozygous or homozygous).
• Contra-indications to MRI scanning according to hospitals 7T MRI screening guideline of the UMCU.
• Patients with severe liver dysfunction.
• Patients with a life expectancy of < 3 months.
• Pregnant or lactating women.
• Claustrofobia.
Exclusion criteria phase 2
• Patients that withdraw treatment with capecitabine and bevacizumab within the first three cycli.

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>7T MRS characteristics on (changes in) concentration of capecitabine and<br /><br>metabolites measured in liver metastasis during MRS examinations obtained at<br /><br>discretized time point(s).</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>Secondary endpoints include response measurements (complete response, partial<br /><br>response, stable disease and progressive disease) according to RECIST and<br /><br>detailed information on perfusion, diffusion and acidity as determined by<br /><br>functional MRI.</p><br>
© Copyright 2025. All Rights Reserved by MedPath